These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 19528812)

  • 1. Assessment of the ion channel-blocking profile of the novel combined ion channel blocker AZD1305 and its proarrhythmic potential versus dofetilide in the methoxamine-sensitized rabbit in vivo.
    Carlsson L; Andersson B; Linhardt G; Löfberg L
    J Cardiovasc Pharmacol; 2009 Jul; 54(1):82-9. PubMed ID: 19528812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit.
    Jacobson I; Carlsson L; Duker G
    J Pharmacol Toxicol Methods; 2011; 63(1):40-6. PubMed ID: 20451633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced ventricular proarrhythmic potential of the novel combined ion-channel blocker AZD1305 versus dofetilide in dogs with remodeled hearts.
    Johnson DM; de Jong MM; Crijns HJ; Carlsson LG; Volders PG
    Circ Arrhythm Electrophysiol; 2012 Feb; 5(1):201-9. PubMed ID: 22080293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the proarrhythmic potential of the novel antiarrhythmic agent AZD7009 and dofetilide in experimental models of torsades de pointes.
    Wu Y; Carlsson L; Liu T; Kowey PR; Yan GX
    J Cardiovasc Electrophysiol; 2005 Aug; 16(8):898-904. PubMed ID: 16101634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vernakalant is devoid of proarrhythmic effects in the complete AV block dog model.
    Varkevisser R; van der Heyden MA; Tieland RG; Beekman JD; Vos MA
    Eur J Pharmacol; 2013 Nov; 720(1-3):49-54. PubMed ID: 24211677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beat-to-Beat variability of repolarization determines proarrhythmic outcome in dogs susceptible to drug-induced torsades de pointes.
    Thomsen MB; Volders PG; Beekman JD; Matz J; Vos MA
    J Am Coll Cardiol; 2006 Sep; 48(6):1268-76. PubMed ID: 16979017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new method to calculate the beat-to-beat instability of QT duration in drug-induced long QT in anesthetized dogs.
    van der Linde H; Van de Water A; Loots W; Van Deuren B; Lu HR; Van Ammel K; Peeters M; Gallacher DJ
    J Pharmacol Toxicol Methods; 2005; 52(1):168-77. PubMed ID: 15935709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcium antagonist property of CPU228, a dofetilide derivative, contributes to its low incidence of torsades de pointes in rabbits.
    Huang ZJ; Dai DZ; Li N; Na T; Ji M; Dai Y
    Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):310-7. PubMed ID: 17324143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of the Na+/Ca2+ exchanger, I(Na) and I(CaL) in the genesis of dofetilide-induced torsades de pointes in isolated, AV-blocked rabbit hearts.
    Farkas AS; Makra P; Csík N; Orosz S; Shattock MJ; Fülöp F; Forster T; Csanády M; Papp JG; Varró A; Farkas A
    Br J Pharmacol; 2009 Mar; 156(6):920-32. PubMed ID: 19222480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiarrhythmic properties of a rapid delayed-rectifier current activator in rabbit models of acquired long QT syndrome.
    Diness TG; Yeh YH; Qi XY; Chartier D; Tsuji Y; Hansen RS; Olesen SP; Grunnet M; Nattel S
    Cardiovasc Res; 2008 Jul; 79(1):61-9. PubMed ID: 18367457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proarrhythmic electrical remodelling is associated with increased beat-to-beat variability of repolarisation.
    Thomsen MB; Oros A; Schoenmakers M; van Opstal JM; Maas JN; Beekman JD; Vos MA
    Cardiovasc Res; 2007 Feb; 73(3):521-30. PubMed ID: 17196569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872.
    Bril A; Gout B; Bonhomme M; Landais L; Faivre JF; Linee P; Poyser RH; Ruffolo RR
    J Pharmacol Exp Ther; 1996 Feb; 276(2):637-46. PubMed ID: 8632331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Models of torsades de pointes: effects of FPL64176, DPI201106, dofetilide, and chromanol 293B in isolated rabbit and guinea pig hearts.
    Cheng HC; Incardona J
    J Pharmacol Toxicol Methods; 2009; 60(2):174-84. PubMed ID: 19524054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atrial-specific drug AVE0118 is free of torsades de pointes in anesthetized dogs with chronic complete atrioventricular block.
    Oros A; Volders PG; Beekman JD; van der Nagel T; Vos MA
    Heart Rhythm; 2006 Nov; 3(11):1339-45. PubMed ID: 17074641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RSD1235 blocks late INa and suppresses early afterdepolarizations and torsades de pointes induced by class III agents.
    Orth PM; Hesketh JC; Mak CK; Yang Y; Lin S; Beatch GN; Ezrin AM; Fedida D
    Cardiovasc Res; 2006 Jun; 70(3):486-96. PubMed ID: 16545351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beat-to-Beat Variability in Preload Unmasks Latent Risk of Torsade de Pointes in Anesthetized Chronic Atrioventricular Block Dogs.
    Stams TR; Oosterhoff P; Heijdel A; Dunnink A; Beekman JD; van der Nagel R; van Rijen HV; van der Heyden MA; Vos MA
    Circ J; 2016 May; 80(6):1336-45. PubMed ID: 27151565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late na(+) current inhibition by ranolazine reduces torsades de pointes in the chronic atrioventricular block dog model.
    Antoons G; Oros A; Beekman JD; Engelen MA; Houtman MJ; Belardinelli L; Stengl M; Vos MA
    J Am Coll Cardiol; 2010 Feb; 55(8):801-9. PubMed ID: 20170820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined pharmacological block of I(Kr) and I(Ks) increases short-term QT interval variability and provokes torsades de pointes.
    Lengyel C; Varró A; Tábori K; Papp JG; Baczkó I
    Br J Pharmacol; 2007 Aug; 151(7):941-51. PubMed ID: 17533421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of a KCNH2 polymorphism (R1047 L) in dofetilide-induced Torsades de Pointes.
    Sun Z; Milos PM; Thompson JF; Lloyd DB; Mank-Seymour A; Richmond J; Cordes JS; Zhou J
    J Mol Cell Cardiol; 2004 Nov; 37(5):1031-9. PubMed ID: 15522280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potassium and calcium current blocking properties of the novel antiarrhythmic agent H 345/52: implications for proarrhythmic potential.
    Amos GJ; Abrahamsson C; Duker G; Hondeghem L; Palmer M; Carlsson L
    Cardiovasc Res; 2001 Feb; 49(2):351-60. PubMed ID: 11164845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.